Featured Stories

The Future of Rabbit Pyrogen Testing


During the last year, the move to replace the rabbit pyrogen test whenever possible has increased, especially in Europe. Companies should start to actively discuss this topic internally in order to determine the path forward.

FcγR-Binding Assays with HTRF Readout Now Available


Charles River now provides FcγR-binding assays with HTRF readout for FcγRI, -II, -III and FcγRn. These assays are used to measure the binding of therapeutic mAbs to Fcγ-receptors and are suitable for assessing biosimilarity.

Breaching the BBB


Intrathecal administration bypasses the blood-brain barrier (BBB) by accessing the spinal canal directly. Our scientists apply this technique to effectively deliver both small and large molecules.

How Do We Support the Fastest-Growing Area of Cancer Research?


Oncotest’s presence in Freiburg, Germany enables Charles River to extend development and availability of our robust portfolio of syngeneic models to clients in Europe, providing further support to immuno-oncology researchers across the globe.

New In Vivo Imaging for Oncology Research


We’ve recently added small animal imaging services at our Oncology Center of Excellence. This valuable tool enhances oncology research by allowing us to monitor molecular and cellular processes in live animals and perform quantitative, longitudinal analysis.

Boost Efficiency with PDX-based Assays


Oncology researchers can save time and money using in vitro 2D and 3D assays in the earliest stages of research. These PDX-based models offer a more targeted approach to evaluate therapeutics and help determine the best in vivo models to use later on.

The Science (and Art) of Ion Channel HTS


The growing interest in ion channel targets has driven a need for effective high-throughput screens. Here, our expert, Dr. Andrew Southan discusses the complex chemistry and biology applications involved in their development.

Displaying results 41-50 (of 64)
 |<  <  1 - 2 - 3 - 4 - 5 - 6 - 7  >  >|